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The impact of the first COVID-19 surge on
severe asthma patients in the UK. Which
is worse: the virus or the lockdown?
To the Editor:
Respiratory viral infections are a significant cause of morbidity in asthma [1]. Patients with severe asthma
were assumed to be at greater risk from novel coronavirus disease 2019 (COVID-19). In the global
response to the COVID-19 pandemic, multiple countries enacted social containment policies. In the UK a
countrywide lockdown occurred in March 2020, with stringent self-isolation (“shielding”) advice for
high-risk patients, including people with severe asthma.
Subsequently, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)
reported that 14% of UK patients hospitalised with COVID-19 had an underlying diagnosis of asthma, but
they did not associate asthma with higher mortality [2]. The OpenSAFELY study of COVID-19-related deaths
identified severe asthma as a factor associated with mortality (hazard ratio 1.13 (1.01–1.26)) [3]. However,
“severe asthma” was defined as anyone with asthma and showing a course of oral corticosteroids (OCS) in
their records in the past year [3]. Their analysis of inhaled corticosteroid (ICS) use showed increased mortality
risk from COVID-19 in asthma patients on high-dose versus no ICS, attributed to unrecorded health
differences between the two groups [4]. The Italian Severe Asthma Registry reported infrequent incidence of
COVID-19, based on participating centres reporting cases of confirmed/highly suspected COVID-19 with
severe asthma, and as 21 out of 26 cases were on anti-interleukin IL-5/IL-5R biologics, it was speculated that
asthma biologics may modulate the risk of COVID-19 [5]. To our knowledge, there is no information on the
burden of social isolation (shielding) in people with severe asthma. There is a need for information on the
impact of COVID-19 on a well-characterised severe asthma population in the community, effects of shielding
and any association between asthma medication and COVID-19.
The UK Severe Asthma Registry (UKSAR) performed an audit in June 2020 across 14 centres of: patient
adherence with shielding advice, potential infection with the COVID-19 virus and outcomes, and asthma
control since March 1, 2020. UKSAR centres with >100 registry patients used randomly generated lists to
reduce potential bias. Where available, electronic hospital records were checked to confirm hospital
admissions and COVID-19 swab/serology results. Permission was obtained by centres as per local audit
requirements, and all patients had previously consented to use of their anonymised registry data.
Confirmed COVID-19 was defined as those with a positive PCR/serology test. Suspected COVID-19 was
defined as typical symptoms, managed clinically as COVID-19, without a negative test. Ambulatory and
hospitalised patients were labelled as “mild” and “severe” COVID-19, respectively. Audit data were combined
with clinical data from the UKSAR. We used data from the most recent visit and imputed missing values with
data collected at previous visits. Univariate analyses were conducted using independent t-tests, Mann–Whitney
U-tests or Chi-squared tests as appropriate. Multivariate analyses were undertaken using logistic regression
adjusting for age, sex, ethnicity, body mass index, site, cardiac disease, diabetes and hypertension.
In total, 1365 patients were included (table 1). Shielding advice was sent to 1268 (93.0%) patients, which
was followed by 1131 (89.2%). Males and members of a non-shielding household were less likely to follow
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TABLE 1 Characteristics of severe asthma patients according to coronavirus disease 2019 (COVID-19) status, disease severity and confirmed COVID-19
Characteristic Subjects COVID-19 status COVID-19 disease severity Confirmed COVID-19
No COVID-19 Suspected or confirmed
COVID-19
p-value Nonhospitalised Hospitalised p-value Confirmed
COVID-19
p-value#
Subjects 1268 97 84 13 19
Age years 1365 52.8±15.5 51.2±13.8 0.313 50.5±13.8 55.6±13.7 0.215 49.8±13.7 0.404
Male sex 1365 453 (35.7%) 43 (44.3%) 0.089 39 (46.4%) 4 (30.8%) 0.290 5 (26.3%) 0.395
BMI kg·m−2 1166 31.0±7.2 31.3±6.1 0.704 31.3±6.3 31.3±4.9 0.967 30.6±6.3 0.849
Smoking status 1322 − − 0.584 − − 0.739 − 0.522
Never-smoker 1322 838 (68.4%) 69 (71.9%) − 59 (71.1%) 10 (76.9%) − 15 (78.9%) −
Ex-smoker 1322 337 (27.5%) 22 (22.9%) − 20 (24.1%) 2 (15.4%) − 3 (15.8%) −
Current smoker 1322 51 (4.2%) 5 (5.2%) − 4 (4.8%) 1 (7.7%) − 1 (5.3%) −
Non-Caucasian ethnicity 1345 150 (12.0%) 18 (18.8%) 0.054 15 (17.9%) 3 (25.0%) 0.553 3 (16.7%) 0.547
Resident in London area 1365 306 (24.1%) 44 (45.4%) <0.001 39 (46.4%) 5 (38.5%) 0.591 11 (57.9%) <0.001
Resident outside London area (rest
of UK)
1365 962 (75.9%) 53 (54.5%) − 45 (53.6%) 8 (61.8%) − 8 (42.1%) −
Atopic disease 1236 662 (57.8%) 58 (64.4%) 0.216 48 (62.3%) 10 (76.9%) 0.310 11 (57.9%) 0.991
Depression or anxiety 1365 126 (9.9%) 9 (9.3%) 0.834 9 (10.7%) 0 (0.0%) 0.215 0 (0.0%) 0.148
Clinic FEV1
¶ % predicted 1113 68.1 (52.9–82.6) 67.9 (59.9–83.4) 0.343 67.9 (59.9–82.8) 73.7
(60.1–84.8)
0.555 80.8 (60.7–86.2) 0.141
Clinic FVC¶ % predicted 1081 83.6 (71.8–95.4) 82.8 (71.3–92.6) 0.779 83.1 (71.3–91.7) 81.2
(68.9–92.6)
0.814 87.3 (76.7–93.9) 0.558
Asthma medication and control




0.002 1600 (1000–2000) 0.106
Maintenance OCS 1363 481 (38.0%) 34 (35.4%) 0.620 30 (35.7%) 4 (33.3%) 0.872 9 (47.4%) 0.402
Maintenance macrolides 1200 153 (13.8%) 9 (10.2%) 0.351 7 (9.9%) 2 (16.7%) 0.428 3 (16.7%) 0.723
Theophylline 1237 294 (25.7%) 12 (13.2%) 0.008 10 (12.8%) 2 (15.4%) 0.800 3 (15.8%) 0.328
Evidence of poor adherence 1190 248 (22.5%) 25 (29.1%) 0.160 18 (24.7%) 7 (53.8%) 0.033 6 (31.6%) 0.346
On asthma biologic 1361 853 (67.5%) 65 (67.0%) 0.924 57 (67.9%) 8 (61.5%) 0.652 13 (68.4%) 0.931
Biologic type 917 − − 0.349 − − 0.986 − 0.841
Anti-IL-5+ 917 680 (79.7%) 55 (85.9%) − 49 (86.0%) 6 (85.7%) − 11 (84.6%) −
Anti-IgE 917 157 (18.4%) 9 (14.1%) − 8 (14.0%) 1 (14.3%) − 2 (15.4%) −
Anti-IL-4/13 917 16(1.9%) 0 (0%) − 0 (0.0%) 0 (0.0) − 0 (0.0%) −
Comorbidities
Cardiac disease 1299 64 (5.3%) 6 (6.3%) 0.678 5 (6.1%) 1 (7.7%) 0.826 1 (5.3%) 0.992
Diabetes 1365 78 (6.2%) 5 (5.2%) 0.692 5 (6.0%) 0 (0.0%) 0.366 1 (5.3%) 0.873
Hypertension 1365 121 (9.5%) 9 (9.3%) 0.932 7 (8.3%) 2 (15.4%) 0.415 2 (10.5%) 0.885
Malignancy 1365 13 (1.0%) 1 (1.0%) 0.996 1 (1.2%) 0 (0.0%) 0.693 0 (0.0%) 0.657
Associated COPD 1365 38 (3.0%) 5 (5.2%) 0.241 4 (4.8%) 1 (7.7%) 0.657 1 (5.3%) 0.567
Shielding and asthma control
during lockdown
Advised to shield 1363 1182 (93.2%) 86 (90.5%) 0.320 76 (90.5%) 10 (90.9%) 0.963 16 (88.9%) 0.470
Followed shielding advice 1268 1058 (89.5%) 73 (84.9%) 0.182 64 (84.2%) 9 (90.0%) 0.631 13 (81.3%) 0.286























Characteristic Subjects COVID-19 status COVID-19 disease severity Confirmed COVID-19
No COVID-19 Suspected or confirmed
COVID-19





76 0 (0.0%) 44 (57.9%) − 40 (60.6%) 4 (40.0%) 0.219 8 (53.3%) −
Non-shielding household 1338 715 (57.3%) 50 (54.9%) 0.656 41 (51.2%) 9 (81.8%) 0.056 14 (77.8%) 0.081
Specialist asthma attendance 1359 432 (34.2%) 31 (32.6%) 0.759 27 (32.1%) 4 (36.4%) 0.779 4 (22.2%) 0.288
Asthma control worse during
lockdown
1358 463 (36.7%) 50 (52.6%) 0.002 41 (48.8%) 9 (81.8%) 0.039 11 (61.1%) 0.033
Acute OCS course during
lockdown
1363 433 (34.2%) 48 (50.0%) 0.002 40 (47.6%) 8 (66.7%) 0.217 13 (68.4%) 0.002
Hospital admission with COVID-19
Admitted to hospital for COVID-19 97 0 (0.0%) 13 (1.4%) − 0 (0.0%) 13 (100%) <0.001 11 (57.9%) −
Oxygen therapy 12 0 (0.0%) 7 (7.2%) − 0 (0.0%) 7 (58.3%) − 7 (36.8%) −
ITU admission for COVID-19 12 0 (0.0%) 2 (2.1%) − 0 (0.0%) 2 (15.4%) − 1 (5.2%) −
Chest radiograph suggestive of
COVID-19
8 0 (0.0%) 7 (87.5%) − 0 (0.0%) 7 (87.5%) − 7 (87.5%) −
Days in hospital¶ 9 − 11 (5, 22) − − 11 (5,22) − 11 (5,22) −
Data are presented as n, mean±SD, n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;
ICS: inhaled corticosteroids; BDP: budesonide dipropionate; OCS: oral corticosteroids; IL: interleukin; ITU: intensive therapy unit; −: no data to present. #: for confirmed COVID-19 versus





















shielding advice (OR 0.40 (0.26-0.62), p<0.001 and OR 0.27 (0.16-0.45), p<0.001, respectively). In total, 44
(57%) patients with suspected and 8 (42%) patients with confirmed COVID-19 were infected before
receiving shielding advice; 14 (77%) confirmed COVID-19 cases occurred in non-shielding households. Of
those that shielded, 582 (47.0%) reported worsening of mental health. Although those with a history of
depression/anxiety were particularly susceptible (OR 2.12 (1.35-3.33), p=0.001), 447 (76.8%) had no such
premorbidity documented. Other characteristics associated with worsening mental health were female sex
(OR 1.59 (1.19-2.13), p=0.001) and an elevated asthma control score (ACQ-6) ⩾1.5 (OR 1.80 (1.23-2.63),
p=0.004). Younger patients (aged <40) were more affected than those >60 (OR 1.56 (1.08-2.33), p=0.020).
Of 1365 patients, 97 (7.1%) had confirmed/suspected COVID-19 and 19 (1.39%) had PCR/
serology-confirmed infection; 13 (0.95%) were hospitalised with COVID-19. The median (interquartile
range) hospital stay was 11 days (5, 22). A higher proportion of hospitalised versus ambulatory patients were
non-Caucasian (25% versus 17.9%, p=0.053). Two patients died; both were Caucasian men aged over 65.
In total, 918 (67.5%) of patients were on a biologic and 735 (80%) of these on anti-IL-5/5R agents. No
association was seen between biologics and risk of COVID-19 (OR 0.73 (0.46-1.14), p=0.165), but they
were associated with better asthma control (OR 0.56 (0.41-0.77), p<0.001) and fewer exacerbations (OR 0.6
(0.44-0.83), p=0.002). There was no difference in the proportion of patients on biologic therapy between
the mild and hospitalised COVID-19 groups (67.9% versus 61.5%, p=0.652). No association was seen
between the type of biologic therapy and COVID-19. Maintenance OCS (mOCS) was not associated with
COVID-19 (OR 1.18 (0.78-1.80), p=0.427); 35 (47.9%) ambulatory patients and 3 (23.0%) hospitalised
patients were on mOCS (p=0.151).
A high dose of ICS (2000 µg beclometasone dipropionate (BDP) equivalent) was no different from a lower
dose ICS (<1000 µg BDP equivalent) in its association with developing COVID-19 (OR 0.64 (0.32-1.31),
p=0.234). However, hospitalised patients were on lower doses of ICS than ambulatory patients (median
(interquartile range) BDP equivalent 1000 µg (800, 1600) versus 2000 µg (1600, 2000), p=0.002)), and a
greater proportion had a history of poor adherence (53.8% versus 24.7%, p=0.033).
In summary, the majority of patients reported receiving and following shielding advice; 47% of shielding
patients reported worsening of mental health, higher than the Office of National Statistics analysis of
shielding patients in England (35%), with similar higher incidence in female and younger patients [6].
We found that monoclonal antibodies for asthma were not associated with increased risk of mild or severe
COVID-19. This agrees with other emerging findings of low incidence of COVID-19 in the severe asthma
population and biologics not affecting clinical outcome [7]. Poor asthma control increases the risk of
severe viral exacerbations, so disease stability from biologics may be protective in itself [8].
Although numbers were small, there was an association seen with high-dose ICS and reduced
hospitalisation from COVID-19. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial
demonstrated that dexamethasone reduced mortality and progression to an intensive care unit in
hospitalised patients [9]. In vitro studies have suggested ICS can reduce viral replication, whilst
pretreatment with ICS has been shown to reduce the risk of acute respiratory distress syndrome in
hospitalised patients [10, 11]. Further studies are required, but our findings support continued use of ICS
at an appropriate dose for asthma control.
The strength of this study is the multicentre inclusion of well-characterised severe asthma patients. In
addition to studying the impact of COVID-19 and effect of asthma medications, we enquired about the
burden of shielding; a consideration when planning for the second wave. Limitations are the small number
of patients hospitalised with COVID-19 preventing detailed analyses for risk factors. We also note that this
study cannot separate out the risk of COVID-19 in an unshielded severe asthma population and that
adherence to shielding was self-reported. Unfortunately, COVID-19 testing was not widely available in the
early months of the pandemic; hence, despite including only patients reporting symptoms distinct from
their usual asthma, the natural symptom overlap between poor asthma control and mild COVID-19 limits
robust conclusions in the “suspected COVID-19” group.
In conclusion, hospitalisation and death occurred in small numbers of this UK severe asthma population.
Adherence to shielding guidance may have contributed to this but led to worsening of mental health in
our patients. Within our limited number of cases, biologic agents for asthma were not associated with
increased risk of infection with the COVID-19 virus or hospitalisation.
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